BRIDGEBIO PHARMA INC. - COMMON STOCK

BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments

03 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces $250 Million Private Placement Equity Financing

25 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

08 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

06 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023

27 Aug 2023 06:15:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023

24 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update

03 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study

31 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

18 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

17 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023

14 Jul 2023 16:01:00 By Nasdaq GlobeNewswire

Burjeel Holdings to Launch Rare Disease Research & Development Project ‘NADER’ in Partnership with US-based BridgeBio Pharma

12 Jul 2023 16:31:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference

20 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

13 Jun 2023 09:33:35 By Nasdaq GlobeNewswire

BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference

08 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

22 May 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

15 May 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

11 May 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update

04 May 2023 07:30:00 By Nasdaq GlobeNewswire